Page 3 - Axsm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Axsm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Axsm Today - Breaking & Trending Today

Axsome Therapeutics (NASDAQ:AXSM) Price Target Increased to $127.00 by Analysts at Citigroup

Axsome Therapeutics (NASDAQ:AXSM – Free Report) had its price target hoisted by Citigroup from $125.00 to $127.00 in a research note issued to investors on Tuesday, Benzinga reports. Citigroup currently has a buy rating on the stock. A number of other equities research analysts have also weighed in on the stock. Cantor Fitzgerald reaffirmed an […] ....

Sakhalinskaya Oblast , United States , Roger Jeffs , Piper Sandler , Ameritas Investment Partners Inc , Cantor Fitzgerald , Axsome Therapeutics Inc , Securities Exchange Commission , Principal Financial Group Inc , Capital Management , American International Group Inc , Wealth Group , Axsome Therapeutics , Free Report , Moderate Buy , Get Free Report , Director Roger Jeffs , Exchange Commission , Financial Group , Investment Partners , American International Group , International Group , Axsome Therapeutics Daily , Nasdaq Axsm , Boost Price Target , Citigroup Inc ,

HC Wainwright Reiterates Buy Rating for Axsome Therapeutics (NASDAQ:AXSM)

HC Wainwright reiterated their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research report report published on Wednesday morning, Benzinga reports. They currently have a $180.00 target price on the stock. Several other equities research analysts have also issued reports on AXSM. Citigroup started coverage on Axsome Therapeutics in a […] ....

United States , Piper Sandler , Roger Jeffs , Cantor Fitzgerald , Securities Exchange Commission , Axsome Therapeutics Inc , Harbour Investments Inc , Third Bancorp , Fifth Third Bancorp , Washington Trust Advisors Inc , Axsome Therapeutics Company Profile , Axsome Therapeutics , Free Report , Moderate Buy , Therapeutics Stock Down , Get Free Report , Director Roger Jeffs , Exchange Commission , Trust Advisors , Captrust Financial Advisors , Financial Advisors , Axsome Therapeutics Daily , Nasdaq Axsm , Reiterated Rating , Hc Wainwright ,

Axsome Therapeutics (NASDAQ:AXSM) PT Lowered to $108.00

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price decreased by equities researchers at Mizuho from $112.00 to $108.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Mizuho’s price objective indicates a potential upside of 30.20% from the company’s previous close. Other […] ....

United States , Piper Sandler , Wealth Group , Royal Bank , American International Group Inc , Axsome Therapeutics Inc , Capital Management , Principal Financial Group Inc , Ameritas Investment Partners Inc , Axsome Therapeutics , Get Free Report , Therapeutics Stock Down , Financial Group , Investment Partners , American International Group , International Group , Axsome Therapeutics Daily , Nasdaq Axsm , Lower Price Target ,

Mizuho Cuts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $108.00

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price lowered by investment analysts at Mizuho from $112.00 to $108.00 in a report issued on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Mizuho’s target price points to a potential upside of 30.92% from the company’s current price. Other […] ....

United States , Piper Sandler , Washington Trust Advisors Inc , Fifth Third Bancorp , Axsome Therapeutics Inc , Third Bancorp , Harbour Investments Inc , Axsome Therapeutics Company Profile , Cantor Fitzgerald , Royal Bank , Tower Research Capital , Axsome Therapeutics , Get Free Report , Trust Advisors , Financial Advisors , Research Capital , Axsome Therapeutics Daily , Nasdaq Axsm , Lower Price Target ,

Axsome Therapeutics (NASDAQ:AXSM) Price Target Cut to $123.00 by Analysts at Royal Bank of Canada

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective dropped by equities researchers at Royal Bank of Canada from $126.00 to $123.00 in a report released on Wednesday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank of Canada’s price target points to a potential upside of 46.50% […] ....

Nova Scotia , United States , Piper Sandler , Vanguard Group Inc , Cantor Fitzgerald , Royal Bank , Axsome Therapeutics Inc , Blackrock Inc , Axsome Therapeutics , Get Free Report , State Street Corp , Street Corp , Axsome Therapeutics Daily , Nasdaq Axsm , Lower Price Target , Royal Bank Of Canada ,